BeOne Medicines (ONC) Cash & Equivalents (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Cash & Equivalents data on file, last reported at $4.8 billion in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 90.42% year-over-year to $4.8 billion in Q1 2026; TTM through Mar 2026 was $4.8 billion, a 90.42% increase from a year earlier, with the FY2025 full-year figure at $4.5 billion, up 73.08% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.8 billion, up from $4.5 billion in the prior quarter.
• Over the last five years, Cash & Equivalents for ONC reached as high as $4.8 billion in Q1 2026 and fell as low as $191000.0 in Q3 2022.
• Historically, Cash & Equivalents has averaged $3.0 billion across 5 years, with a median of $3.1 billion in 2023.
• Across the five-year window, Cash & Equivalents slumped 99.99% in 2022 and jumped 1605835.08% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $3.9 billion in 2022, then retreated by 18.03% to $3.2 billion in 2023, then decreased by 17.16% to $2.6 billion in 2024, then jumped by 73.08% to $4.5 billion in 2025, then increased by 5.37% to $4.8 billion in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $4.8 billion in Q1 2026, $4.5 billion in Q4 2025, and $4.0 billion in Q3 2025.